Abstract：【Objective】To observe the efficacy of apatinib mesylate tablets in the treatment of advanced gastric cancer and to provide reference for clinical treatment. 【Methods】A total of 70 patients with advanced gastric cancer after first-line chemotherapy (FOLFOX regimen) were randomly divided into two groups. The control group was treated with tigio and the observation group was treated with apatinib mesylate tablets. The clinical efficacy of the two groups after treatment was analyzed. 【Results】In the observation group, there was 1 case of complete remission and 15 cases of partial remission. The objective remission rate was 45.71%. There were 0 cases of complete remission in the control group and 14 cases of partial remission. The objective remission rate was 40.00% (14/35). There was no significant difference in the objective remission rate between the two groups (P>0.05). There was no significant difference in the levels of interferon-gamma (INF- γ), IL-4 (IL-4), serum sugar chain antigen 19- 9 (CA19-9), and sugar chain antigen 72 -4 (CA72-4) between the two groups before treatment (P>0.05). After treatment, the levels of INF- γ and IL-4, CA19-9, CA72-4 in the two groups were higher than those before treatment, and the levels of INF- γ and IL-4, CA19-9, and CA72-4 in the observation group were better than those in the control group after treatment (P<0.05). The incidence of hypertension (22.86%) was higher in the observation group than in t the control group (5.71%), the incidence of diarrhea (11.43%) was lower than that in the control group (31.43%), and the incidence of nausea and vomiting (8.57%), hand and foot syndrome (2.86%), and neutropenia (0.00%) were lower than those of the control group (11.43%, 5.71%, 5.71%, respectively). The difference was statistically significant (P<0.05). 【Conclusion】Apatinib mesylate tablets and tigio tablets have similar efficacy in the treatment of advanced gastric cancer. Apatinib mesylate tablets have more obvious improvement on related cytokines, but attention should be paid to the occurrence of hypertension.
刘甫, 马沛, 魏海. 甲磺酸阿帕替尼片治疗晚期胃癌的疗效[J]. 医学临床研究, 2021, 38(6): 883-885.
LIU Fu, MA Pei, WEI Hai. Efficacy of Apatinib Mesylate Tablets in the Treatment of Advanced Gastric Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 883-885.
[1] 毛爱芹,张育荣,李宝奇,等.CA19-9、CA72-4 和CEA 在阿帕替尼治疗胃癌患者中的变化及意义[J].标记免疫分析与临床,2018,25(5):657-660. [2] 高金平,韩涛,朴瑛,等.阿帕替尼联合替吉奥治疗老年或瘦弱患者晚期胃癌临床研究[J].临床军医杂志,2017,45(1):9-12. [3] 李国强,朱巍,武云.髓样锌指蛋白1 与胃癌关系的研究现状[J].癌症进展,2017,15(7):737-739. [4] NONAGASE Y,YONESAKA K,KAWAKAMI H,et al.Heregulin expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib,trastuzumab and T-DM1[J].Oncotarget,2016,7(51):84860-84871. [5] 李鹏,李成浩.晚期胃癌治疗中阿帕替尼片联合奥沙利铂注射液和替吉奥胶囊的临床疗效及安全性对比分析[J].河北医学,2017,23(11):1923-1926. [6] ROVIELLO G,RAVELLIi A,POLOM K,et al.Apatinib:a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer[J].Cancer Lett,2016,372(2):187-191. [7] 陈希,苏小琴,顾红兵,等.阿帕替尼与伊立替康为主的化疗在胃癌三线治疗中的效果比较及安全性研究[J].南通大学学报(医学版),2017,37(6):562-564. [8] FUKUCHI M,MOCHIKL E,ISHIGURO T,et al.Efficacy of nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer[J].Anticancer Res,2016,36(12):6699-6703. [9] 孙培培,张龙,张泰,等.单药阿帕替尼治疗二线及二线以上化疗失败的晚期大肠癌患者疗效分析[J].临床肿瘤学杂志,2017,22(7):646-649. [10] PRESS MF,ELLIS CE,GAGNON R C,et al.HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib[J].Mol Cancer Ther,2017,16(1):228-238. [11] 吴军,张俊玲,王婧,等.黄芪多糖通过抑制磷酸化蛋白激酶B表达增强阿帕替尼抗胃癌细胞作用的研究[J].中国医院用药评价与分析,2017,17(6):731-734. [12] 丁露,夏云红,王为民,等.甲磺酸阿帕替尼和替吉奥治疗晚期胃癌的疗效和预后观察[J].安徽卫生职业技术学院学报,2017,16(2):48-49,133.
2021, Vol. 38 
